Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer: Implications for paracrine growth

Journal of Pathology

Volumn 188, Issue 3, 1999, Pages 278-281

  Doherty, Alan ^a   Smith, Gillian ^a   Banks, Linda ^a   Christmas, Timothy ^a   Epstein, Richard J ^a,b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Insulin like growth factor binding proteins; Insulin like growth factors; Osteosclerosis; Prostate specific antigen; Prostatic neoplasms; Serine proteases

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN;

ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; BONE LESION; BONE MATRIX; BONE METASTASIS; BONE RADIOGRAPHY; CANCER GROWTH; HUMAN; HUMAN TISSUE; OSTEOBLAST; OSTEOSCLEROSIS; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION;

BONE NEOPLASMS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; OSTEOBLASTS; OSTEOSCLEROSIS; PARACRINE COMMUNICATION; PHENOTYPE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0033053056     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199907)188:3<278::AID-PATH358>3.0.CO;2-G     Document Type: Article

References (38)

1. Body JJ. Metastatic bone disease: clinical and therapeutic aspects. Bone 1992; 13 (Suppl 1): S57-S62.
2. McKinley WO, Conti-Wyneken AR, Vokac CW, Cifu DX. Rehabilitative functional outcome of patients with neoplastic spinal cord compressions. Arch Phys Med Rehab 1996; 77: 892-895.
3. Galasko CS. Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop Relat Res 1982; 169: 20-27.
4. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med 1995; 1: 944-949.
5. Cramer SD, Chen Z, Peehl DM. Prostate-specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 1996; 156: 526-531.
6. Ishibe M, Rosier RN, Puzas JE. Human prostatic acid phosphatase directly stimulates collagen synthesis and alkaline phosphatase content of isolated bone cells. J Clin Endocrinol Metab 1991; 73: 785-792.
7. Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-β and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 1993; 192: 940-947.
8. Schmid C, Rutishauser J, Schläpfer I, Froesch ER, Zapf J. Intact but not truncated insulin-like growth factor binding protein-3 (IGFBP-3) blocks IGF I-induced stimulation of osteoblasts: control of IGF signalling to bone cells by IGFBP-3-specific proteolysis. Biochem Biophys Res Commun 1991; 179: 579-585.
9. Figueroa JA, Lee AV, Jackson JG, Yee D. Proliferation of human prostate cancer cells is inhibited by IGFBP-1: evidence for an IGF-II autocrine growth loop. J Clin Endocrinol Metab 1995; 80: 3476-3482.
10. Meyer GE, Yu E, Siegal JA, et al. Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 1995; 76: 2304-2311.
11. Hiaramatsu M, Kashimata M, Minami N, Sato A, Murayama M. Androgenic regulation of epidermal growth factor in the mouse ventral prostate. Biochem Int 1988; 17: 311-317.
12. Canalis E, McCarthy T, Centrella M. Growth factors and the regulation of bone remodeling. J Clin Invest 1988; 81: 277-281.
13. Ware JL. Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev 1993; 12: 287-301.
14. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkman AO, Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 1996; 271: 6379-6388.
15. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A 1986; 83: 3166-3170.
16. Cohen P, Graves H, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992; 75: 1046-1053.
17. Cohen P, Lamson G, Okajima T, Rosenfeld RG. Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth. Mol Endocrinol 1993; 7: 380-386.
18. Karas M, Danilenko M, Fishman D, LeRoith D, Levy J, Sharoni Y. Membrane-associated IGFBP-3 inhibits IGF1-induced IGF1 receptor signalling in Ishikawa endometrial cancer cells. J Biol Chem 1997; 272: 16514-16520.
19. Rajah R, Valentinis B, Cohen P. IGFBP3 induces apoptosis and mediates the effect of TGF-beta on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997; 272: 12181-12188.
20. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54: 5474-5478.
21. Leal SM, Liu Q, Huang SS, Huang JS. The type V transforming growth factor-beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem 1997; 272: 20572-20576.
22. Oommen R, Geethanjali FS, Gopalakrishnan G, et al. Correlation of serum prostate specific antigen levels and bone scintigraphy in prostate carcinoma. Br J Radiol 1994; 67: 469-471.
23. Andriole GL, Catalona WJ. PSA and bone scans (Letter). J Urol 1992; 147: 474.
24. Oesterling JE. Using PSA to eliminate the staging radionuclide bone scan. Urol Clin North Am 1993; 20: 705-711.
25. Cohen RJ, Haffejee Z, Steele GS, Nayler SJ. Advanced prostate cancer with normal PSA values. Arch Pathol Lab Med 1994; 118: 1123-1126.
26. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. J Am Med Assoc 1993; 269: 57-60.
27. Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M. Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem 1986; 154: 138-143.
28. Cohen P, Peehl DM, Graves H, Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 1994; 142: 407-415.
29. Kanety H, Madjar Y, Dagan Y, et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlations with serum prostate-specific antigen. J Clin Endocrinol Metab 1993; 77: 229-233.
30. Soloway MS, Hardeman SW, Mickey D, Raymond J, Todd B, Moinuddin M. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1992; 62: 195-202.
31. Morote J, Lorente JA, Encabo G. Prostate carcinoma staging: clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. Cancer 1996; 78: 2374-2378.
32. Mohan S, Baylink DJ. Bone growth factors. Clin Orthop Relat Res 1991; 263: 30-48.
33. Stein GS, Lian JB, Stein JL, van Wijnen AJ, Montecino M. Transcriptional control of osteoblast growth and differentiation. Physiol Rev 1996; 76: 593-629.
34. Rosen CJ, Donahue LR, Hunter SJ. Insulin-like growth factors and bone: the osteoporosis connection. Proc Soc Exp Biol Med 1994; 206: 83-102.
35. Thrasher JB, Tennant MK, Twomey PA, Hansberry KL, Wettlaufer SN, Plymate SR. Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations. J Urol 1996; 155: 999-1003.
36. Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia J Urol 1990; 143: 747-752.
37. Lee C, Sutkowski DM, Sensibar JA, et al. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995; 136: 796-803.
38. Karr JF, Kantor JA, Hand PH, Eggensperger DL, Schlom J. The presence of PSA-related genes in primates and the expression of recombinant PSA in a transfected murine cell line. Cancer Res 1995; 55: 2455-2462.